BioSpace News Archive

Saranas announced its Early Bird Bleed Monitoring System has received an Innovative Technology contract from Vizient, Inc., the nation’s largest member-driven health care performance improvement company.

CorMedix Inc. today announced the formation of a new Scientific Advisory Board (SAB) comprised of esteemed experts in nephrology, infectious disease, medical nutrition, and pediatric oncology.

Integer Holdings Corporation announced the acquisition of Connemara Biomedical Holdings Teoranta, including its operating subsidiaries Aran Biomedical and Proxy Biomedical.

Arterys, the world’s leading vendor-neutral AI platform, has announced several new modules to its already robust Cardio AI clinical application and an additional FDA AI clearance based on deep learning.

DiaCarta Inc. announced the appointment of Jack Kaye, retired Partner with Deloitte LLP, as an independent board member who will serve as the Chairman of the Company’s Audit Committee.

Medical technology company, Pneuma Systems Corporation, has entered a multi-faceted business collaboration with West Pharmaceutical Services, Inc. (NYSE: WST) with the goal of improving the patient’s experience with drug therapy.

Codetta Biosciences, the pioneer in digital spatial polymerase chain reaction (dsPCR) and digital spatial immuno polymerase chain reaction (dsiPCR), announced today that it has raised $15 million in Series A financing, led by Anzu Partners with additional funding from Genoa Ventures and VC23 LLC.

Electromedical Technologies, Inc. (OTCQB: EMED) (“Electromedical” or the “Company”), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain by using frequencies and electro-modulation, is pleased to announce its results for the year ended December 31, 2021.

Akston Biosciences Corporation, announced today that the first volunteers in a Phase II/III clinical study of AKS-452, its low cost, shelf stable protein subunit COVID-19 vaccine, were dosed in India. India’s Central Drugs Standard Control Organization (CDSCO) approved the double-blind, placebo-controlled trial, initiated by Ahmedabad-based Veeda Clinical Research Limited, whose data will be submitted in an application for Emergency Use Authorization (EUA).

BioInvent International AB announced that the Annual Report for 2021 has been published.